A950210 Stock Overview
A biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Prestige BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,100.00 |
| 52 Week High | ₩16,220.00 |
| 52 Week Low | ₩7,610.00 |
| Beta | 1.19 |
| 11 Month Change | 10.22% |
| 3 Month Change | 64.31% |
| 1 Year Change | 49.21% |
| 33 Year Change | -42.80% |
| 5 Year Change | n/a |
| Change since IPO | -53.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| A950210 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 8.0% | -3.9% | -3.9% |
| 1Y | 49.2% | 45.5% | 4.8% |
Return vs Industry: A950210 exceeded the KR Biotechs industry which returned 45.5% over the past year.
Return vs Market: A950210 exceeded the KR Market which returned 4.8% over the past year.
Price Volatility
| A950210 volatility | |
|---|---|
| A950210 Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A950210's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A950210's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | So-Yeon Park | www.prestigebiopharma.com |
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor.
Prestige BioPharma Limited Fundamentals Summary
| A950210 fundamental statistics | |
|---|---|
| Market cap | ₩171.63b |
| Earnings (TTM) | -₩32.92b |
| Revenue (TTM) | ₩689.08m |
263.4x
P/S Ratio-5.5x
P/E RatioIs A950210 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950210 income statement (TTM) | |
|---|---|
| Revenue | ₩689.08m |
| Cost of Revenue | ₩1.22b |
| Gross Profit | -₩528.79m |
| Other Expenses | ₩32.39b |
| Earnings | -₩32.92b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.74k |
| Gross Margin | -76.74% |
| Net Profit Margin | -4,777.60% |
| Debt/Equity Ratio | 20.1% |
How did A950210 perform over the long term?
See historical performance and comparison